eligibility_summary
Eligibility: Adults ≥18 with unresectable/recurrent/metastatic HER2+ or HER2-low salivary gland cancer. HER2+: measurable or not, HER2-low: measurable. Brain/lepto OK if no immediate CNS tx. ECOG 0–2, LVEF ≥50%, adequate organ function, baseline imaging. Controlled HIV/HBV/HCV ok. Exclude: cohort-specific prior therapy, serious comorbidity, ILD/pneumonitis, major bleed, neuropathy ≥3 (HER2+), drug allergy, excess anthracycline, recent live vaccine (HER2-low), pregnancy/nursing.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II NCT05408845 tests HER2-targeted therapies in recurrent/metastatic or unresectable salivary gland cancers. Arm I: docetaxel (taxane microtubule stabilizer) + trastuzumab (anti-HER2 IgG1 mAb) to block ERBB2 signaling and induce ADCC. Arm II: ado-trastuzumab emtansine (T-DM1), an antibody–drug conjugate (ADC) that targets HER2 and delivers DM1 (maytansinoid microtubule inhibitor). Arm III: trastuzumab deruxtecan (T-DXd), an ADC that targets HER2 and delivers deruxtecan (topoisomerase I inhibitor) with a membrane-permeable payload enabling bystander killing. Targets: HER2-positive or HER2-low tumor cells, pathways: HER2/ERBB2 signaling (MAPK/PI3K), microtubule dynamics, DNA replication/repair via topo I, plus Fc-mediated immune ADCC.